Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED STATEMENTS OF OPERATIONS

v3.23.1
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
 1 Months Ended 11 Months Ended 12 Months Ended
Dec. 31, 2021
Dec. 02, 2021
Dec. 31, 2022
Financial Designation, Predecessor and Successor [Fixed List] Successor Predecessor Successor
OPERATING REVENUE:      
TOTAL OPERATING REVENUE $ 58,762 $ 578,602 $ 1,049,471
OPERATING EXPENSE:      
Medical expense 66,877 592,465 1,057,224
Premium deficiency reserve 26,277 11,559 (11,461)
Corporate, general and administrative expense 16,983 100,243 157,284
Sales and marketing expense 364 1,818 5,096
Depreciation and amortization 7,149 1,575 87,289
Goodwill impairment 0   1,314,952
TOTAL OPERATING EXPENSE 117,650 707,660 2,610,384
OPERATING LOSS (58,888) (129,058) (1,560,913)
OTHER INCOME (EXPENSE):      
Interest expense, net (851) (9,824) (11,404)
Mark-to-market of stock warrants 2,272 (7,665) 9,865
Other (471) 147 2,757
TOTAL OTHER INCOME (EXPENSE) 950 (17,342) 1,218
LOSS BEFORE INCOME TAXES (57,938) (146,400) (1,559,695)
PROVISION FOR INCOME TAXES     (1,862)
NET LOSS (57,938) (146,400) (1,561,557)
LESS: NET LOSS ATTRIBUTABLE TO REDEEMABLE NON-CONTROLLING INTERESTS (47,857)   (1,291,430)
NET LOSS ATTRIBUTABLE TO CONTROLLING INTERESTS $ (10,081) (146,400) $ (270,127)
NET LOSS PER SHARE (BASIC) $ (0.24)   $ (6.50)
NET LOSS PER SHARE (DILUTED) $ (0.24)   $ (6.50)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING (BASIC) 41,579   41,579
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING (DILUTED) 41,579   41,579
Capitated revenue      
OPERATING REVENUE:      
TOTAL OPERATING REVENUE $ 57,224 567,735 $ 1,034,800
Other patient service revenue      
OPERATING REVENUE:      
TOTAL OPERATING REVENUE $ 1,538 $ 10,867 $ 14,671